Compare Adaptive Biotechnologies Corp (ADPT) vs LTC Properties Inc (LTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs LTC Properties Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while LTC Properties Inc trades at $39.34 (market cap $2.01B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and LTC Properties Inc pays a 5.81% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LTC | |
|---|---|---|
Market Cap | $3.33B | $2.01B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $40.36 |
52-Week Low | $10.24 | $33.98 |
Enterprise Value | $3.19B | $2.86B |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
LTC Properties trades at $39.23, down 0.13% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.69, missing expectations of $0.72, but revenue grew to $263M in 2025. Analyst consensus is mixed with 27% buy ratings, while recent news highlights dividend declarations and a $54M SHOP acquisition, reinforcing its focus on senior housing investments.
Outlook remains supported by demographic trends in senior housing, though earnings misses and high debt levels pose risks. The stock offers a monthly dividend, but investors face headwinds from execution challenges in shifting to SHOP strategy and interest rate sensitivity due to substantial leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
